Skip to main content
Premium Trial:

Request an Annual Quote

Mediomics Lands $460K STTR Grant

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Mediomics has reeled in $460,000 from the National Institute of General Medical Sciences through a Phase II Small Business Technology Transfer (STTR) grant.

The company plans to use the funds to develop and increase the sensitivity of its biosensor technology and to develop its PINCER protein assay. Mediomics is commercializing core technologies it has licensed under an exclusive agreement with Saint Louis University.

Mediomics' technologies include a DNA-binding protein-based bioassay and biochip platform; the related molecular PINCER-based biosensor, bioassay, and biochip platforms; and methods for screening and developing new high affinity capture reagents for research, diagnostic, and therapeutic applications.

The St. Louis-based company is focused on developing assay kits, biosensors, and microarrays for academic and corporate research, point-of-care testing, process control, and the medical and environmental research markets. These assays will be used to quantify important macromolecules, including ligands, proteins, protein complexes, and pathogens.

The company said it also plans to develop high-throughput screening kits for drug discovery targets and to support expansion into clinical diagnostic markets.